A novel Artificial Intelligence-based tool to assess anticholinergic burden: a survey.
adverse events
anticholinergic
older people
polypharmacy
Journal
Age and ageing
ISSN: 1468-2834
Titre abrégé: Age Ageing
Pays: England
ID NLM: 0375655
Informations de publication
Date de publication:
02 08 2022
02 08 2022
Historique:
received:
15
02
2022
entrez:
27
8
2022
pubmed:
28
8
2022
medline:
31
8
2022
Statut:
ppublish
Résumé
many medications possess anticholinergic activity. Their use is associated with a number of serious adverse effects including cognitive effects. The cumulative anticholinergic effect of medications as assessed by tools such as the anticholinergic burden scale (AchB) can identify people particularly at risk of anticholinergic side-effects. Currently, >20 tools are available for clinicians to use, but there is no consensus on the most appropriate tool. a newly created online tool-International Anticholinergic Cognitive Burden Tool (IACT)-based on natural language processing and chemical structure analysis, was developed and made available for clinicians to test its functions. We carried out a survey (between 8th of February and 31st of March 2021) to assess the overall need for an assessment tool as well as the usability of the IACT. a total of 110 responses were received from different countries and practitioners' groups. The majority of the participants (86.11%) stated they would use a tool for AchB assessment if available and when they were asked to rate the IACT against other tools, amongst 34 responders, 20.59% rated it better and 8.82% rated it significantly better, 44.12% rated it neither better, nor worse, 14.71% rated it worse and 11.76% somewhat worse. there is a need for an anticholinergic burden calculator to assess the anticholinergicity of medications. Tools such as the IACT potentially could meet this demand due to its ability to assign scores to current and new medications appearing on the market based both on their chemical structure and reported adverse pharmacological effects.
Sections du résumé
BACKGROUND
many medications possess anticholinergic activity. Their use is associated with a number of serious adverse effects including cognitive effects. The cumulative anticholinergic effect of medications as assessed by tools such as the anticholinergic burden scale (AchB) can identify people particularly at risk of anticholinergic side-effects. Currently, >20 tools are available for clinicians to use, but there is no consensus on the most appropriate tool.
METHODS
a newly created online tool-International Anticholinergic Cognitive Burden Tool (IACT)-based on natural language processing and chemical structure analysis, was developed and made available for clinicians to test its functions. We carried out a survey (between 8th of February and 31st of March 2021) to assess the overall need for an assessment tool as well as the usability of the IACT.
RESULTS
a total of 110 responses were received from different countries and practitioners' groups. The majority of the participants (86.11%) stated they would use a tool for AchB assessment if available and when they were asked to rate the IACT against other tools, amongst 34 responders, 20.59% rated it better and 8.82% rated it significantly better, 44.12% rated it neither better, nor worse, 14.71% rated it worse and 11.76% somewhat worse.
CONCLUSION
there is a need for an anticholinergic burden calculator to assess the anticholinergicity of medications. Tools such as the IACT potentially could meet this demand due to its ability to assign scores to current and new medications appearing on the market based both on their chemical structure and reported adverse pharmacological effects.
Identifiants
pubmed: 36029230
pii: 6677534
doi: 10.1093/ageing/afac196
pmc: PMC9419503
pii:
doi:
Substances chimiques
Cholinergic Antagonists
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the British Geriatrics Society.
Références
Ann Med. 2017 Mar;49(2):157-164
pubmed: 27763767
Maturitas. 2020 Dec;142:55-63
pubmed: 33158488
Neurol Sci. 2009 Apr;30(2):87-92
pubmed: 19229475
Front Pharmacol. 2016 Oct 05;7:358
pubmed: 27761112
Aging Clin Exp Res. 2016 Feb;28(1):25-35
pubmed: 25930085
Front Pharmacol. 2020 Apr 29;11:570
pubmed: 32411001
J Am Med Dir Assoc. 2021 Jan;22(1):56-64
pubmed: 32709405
Age Ageing. 2015 Mar;44(2):219-25
pubmed: 25430550
BMC Geriatr. 2020 Jul 31;20(1):267
pubmed: 32736640
J Am Geriatr Soc. 2015 Jan;63(1):85-90
pubmed: 25597560
Drugs Aging. 2015 Oct;32(10):835-48
pubmed: 26442862
J Am Med Dir Assoc. 2020 Feb;21(2):172-180.e5
pubmed: 31351858
North Clin Istanb. 2021 Mar 11;8(2):139-144
pubmed: 33851077
Br J Clin Pharmacol. 2004 Jan;57(1):6-14
pubmed: 14678335
Br J Clin Pharmacol. 2015 Aug;80(2):209-20
pubmed: 25735839
PLoS One. 2021 Jun 30;16(6):e0253336
pubmed: 34191827
Arch Gerontol Geriatr. 2020 Mar - Apr;87:103885
pubmed: 31155228
Age Ageing. 2014 Sep;43(5):604-15
pubmed: 25038833
Drugs Aging. 1993 Jul-Aug;3(4):335-48
pubmed: 8369593
J Am Geriatr Soc. 2011 Aug;59(8):1477-83
pubmed: 21707557
Cochrane Database Syst Rev. 2021 May 5;5:CD013540
pubmed: 34097766